Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00988858 | A Study of Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 17, 2019 | clinicaltrials |
| NCT01160744 | A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 280 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 13, 2019 |
| NCT02448303 | Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer(KEYNOTE166) | completed | Phase 2 | 74 | Acerta Pharma BVINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02843815 | Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02845856 | Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01107444 | Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 180 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 11, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01469000 | A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 195 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 10, 2019 | clinicaltrials |
| NCT03228277 | Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA | completed | Phase 2 | 25 | Konkuk University Medical CenterOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT00065182 | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer | completed | Phase 2 | 399 | GlaxoSmithKlineINDUSTRY | 3 | Jun 24, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00198367 | Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 120 | Hospices Civils de LyonOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT00548093 | PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib | completed | Phase 2 | 66 | PfizerINDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT01866410 | Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 16, 2019 | clinicaltrials |
| NCT00387465 | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | May 9, 2019 | clinicaltrials |
| NCT02176369 | Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial(ONC-MANILA12) | completed | Phase 2 | 120 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02054052 | Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer | completed | Phase 2 | 22 | Haihong Yang, MD, Pricipal investigatorOTHER | 1 | Mar 29, 2019 | clinicaltrials |
| NCT01685138 | LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 26, 2019 | clinicaltrials |
| NCT00614822 | Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer(H3E-US-X072) | completed | Phase 2 | 50 | Christiana Care Health ServicesOTHER | 0 | Mar 20, 2019 | clinicaltrials |
| NCT01949701 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01950156 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02340208 | A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 | completed | Phase 1 / Phase 2 | 76 | Helix BioPharma CorporationINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01487265 | Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT00459342 | Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02040870 | LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 1 / Phase 2 | 103 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT01415011 | Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients(TIMELY) | completed | Phase 2 | 39 | University College, LondonOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00918203 | A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 137 | Eli Lilly and CompanyINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01465802 | Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO(ARCHER 1042) | completed | Phase 2 | 236 | PfizerINDUSTRY | 2 | Jan 9, 2019 | clinicaltrials |
| NCT00125359 | Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer | completed | Phase 2 | 42 | Konstantin DragnevOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01846416 | A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] | completed | Phase 2 | 138 | Genentech, Inc.INDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00385996 | Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 28, 2018 | clinicaltrials |
| NCT00567359 | Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR | completed | Phase 2 | 100 | Massachusetts General HospitalOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT02289456 | Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2(AboundPS2) | completed | Phase 2 | 40 | CelgeneINDUSTRY | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02655913 | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer(VCONSCLC) | completed | Phase 1 / Phase 2 | 97 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Nov 30, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT01260181 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 30 | Hoffmann-La RocheINDUSTRY | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00363766 | Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 19, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT00864721 | Sunitinib Non Small Cell Lung Cancer Patients Over 70 | completed | Phase 2 | 63 | US Oncology ResearchINDUSTRY | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02875340 | A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 8 | ValiSeek LimitedINDUSTRY | 0 | Oct 15, 2018 | clinicaltrials |
| NCT00188279 | Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma | completed | Phase 2 | 311 | University Health Network, TorontoOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00994097 | NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 121 | AGC Biologics S.p.A.INDUSTRY | 1 | Sep 27, 2018 | clinicaltrials |
| NCT00252382 | Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC | completed | Phase 2 | 31 | Sunesis PharmaceuticalsINDUSTRY | 1 | Sep 24, 2018 | clinicaltrials |
| NCT01174563 | A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01310036 | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 17, 2019source: clinicaltrials